Table 3.
Patients’ baseline characteristics and adherence
| Age at treatment initiation | |
| Median (IQR) | 40 (33–47) |
| >50 years | 61 (15.14) |
| ≤50 years | 342 (84.86) |
| Female | 243 (60.3) |
| HIV type | |
| HIV1 | 377 (93.5) |
| HIV2 | 11 (2.7) |
| HIV dual | 15 (3.7) |
| Karnofsky score median (IQR) | 90 (90–100) |
| Groups of eligible patients for ART | |
| Asymptomatic patients with CD4 cell count of <200/mm3 | 31 (7.69) |
| Symptomatic patients (CDC stage B) with CD4 cell count of <350/mm3 | 273 (67.74) |
| Symptomatic patients (CDC stage C) irrespective of CD4 cell count | 99 (24.57) |
| Baseline CDC clinical stage | |
| Stages A and B | 304 (75.43) |
| Stage C | 99 (24.56) |
| Baseline CD4 cell count/mm3 | |
| Median (IQR) | 137 (64–211) |
| <200 | 291 (72.2) |
| ≥200 | 112 (27.8) |
| Presence of opportunistic infections | 207 (51.4) |
| ART regimens | |
| NNRTI-based regimen | 374 (92.8) |
| PI-based regimen | 23 (5.6) |
| 3 NRTIs regimen | 6 (1.5) |
| Patients with cotrimoxazole prophylaxis | 377 (93.5) |
| Good adherence to ART | |
| M6 | 383 (95) |
| M12 | 364 (90.32) |
| M18 | 375 (93) |
| M24 | 350 (86.8) |
Note: Data presented as n (%) unless otherwise stated.
Abbreviations: ART, antiretroviral therapy; CDC, Centers for Disease Control and Prevention; HIV, human immunodeficiency virus; IQR, interquartile range; M6, 6 months; M12, 12 months; M18, 18 months; M24, 24 months; NRTI, nucleoside reverse transcriptase inhibitor; NNRTI, nonnucleoside reverse transcriptase inhibitor; PI, protease inhibitor.